Hey There : )
Unlisted Shares
Price Chart
1W
1M
1Y
MAX
High
-
Low
-
Return
-
Intas Pharmaceuticals Essentials
As of September 08, 2024, Intas Pharmaceuticals, Unlisted share price is ₹5800.00 per share and the face value is ₹10.00/share. The lot size of Intas Pharmaceuticals is None shares. The 52-week high for Intas Pharmaceuticals stock price is ₹5800, while the 52-week low is ₹5800
An International Securities Identification Number (ISIN) is a code that uniquely identifies a specific securities issue. The numbers are allocated by a country's respective national numbering agency (NNA).
Value of a security, as stated by its issuer. It has no relation with market price of the stock.
Total shares or total number of shares outstanding represents the amount of stock on the open market, including shares held by institutional investors and restricted shares held by insiders and company officers.
Gross income refers to the total income earned by an individual on a pay check before taxes and other deductions. It comprises all incomes received by an individual from all sources – including wages, rental income, interest income, and dividends.
It is the final profit left over after subtracting all operating and non operating items from net revenue.
It is the profit allocated to each outstanding share of common stock.
It is a valuation parameter that measures the company's current share price relative to its per-share earnings. Generally, high P/E is Overvalued & low P/E is Undervalued.
It shows the relationship between the current price and the book value of each share. A lower P/B ratio can mean that the stock is undervalued.
Market capitalization is the aggregate valuation of the company based on its current share price and the total number of outstanding shares.
It measures companys total value, which includes market capitalization, debt and excludes cash.
It calculates the per share value of a company based on its equity available to common shareholders
Intrinsic value is the anticipated value of a company or stock determined through fundamental analysis. It is also referred to as the price a rational investor is willing to pay for an investment, given its level of risk.
It measures the amount of cash dividends distributed to equity shareholders relative to the market value per share.
A sector is an area in which businesses share the same or a related product or service. It can also be known as an industry or market that shares common operating characteristics
Subsectors are the divisions of a sector. They are areas that vary from the rest of the sector substantially enough to justify creating a plan just for the subsector.
Category is defined as a class or division of things regarded as having particular shared characteristics.
It indicates the amount of money a company brings in from its ongoing and regular operations over a fixed period of time.
It shows the net flows of cash that are used to fund the company, which include transactions involving debt, equity, and dividends.
Intas Pharmaceuticals Growth
Compounded Sales Growth
Compounded Profit Growth
Return On Equity
Highlights
- Global Presence - Intas Pharmaceuticals has a strong global presence, with operations in over 85 countries worldwide. The company's has a product portfolio of > 10,000 across various international markets such as Asia, Africa, Europe, Latin America, and North America. It is worth noting that the company earns >60% of its revenue from overseas markets such as Europe/Asia, hence the company is always exposed to foreign policy changes. However, the company's hedging strategy mitigates the majority of the risk.
- Revenue Growth - The company's revenue has experienced a substantial rise, climbing from ₹18,351 crore in FY22 to ₹19,882 crore in FY23, indicating a growth rate of 8.25%. Over the past five years, the company's revenue has consistently increased, achieving a compound annual growth rate (CAGR) of 13.07% from FY18 to FY23.
- Profitability - The company's profitability has maintained consistency over time. The EBIT margin, which was 19.7% in FY18, has decreased to 15.3% in FY23, reflecting a CAGR of -4.95%. Likewise, the net profit margin of the company has also been almost consistent from 12.3% in FY18 to 12.3% in FY23. The net profit has increased by a CAGR OF 12.1% over past 5 years. The profitability has decreased in FY23 compared to FY22 due to the increased costs. It is worth noting that the increase in expenses is related to ESOP liquidation. In FY23, the company has issued the shares for Rs. 5,475
- Investment Thesis - When benchmarking Intas Pharmaceuticals against industry peers, the average price-to-earnings (P/E) ratio is approximately 32.17x. Factoring in the discounts, the share price falls within the range of ₹4,753 to ₹5,092. Given the positive indicators in terms of revenue growth and profitability, the company appears to be fairly valued, presenting a promising investment opportunity for investors.
- Kindly note, that the company has received a warning letter from the FDA against its manufacturing facility in Ahmedabad. Any further regulatory non-compliance issued to the company for its products and/or manufacturing facilities, which may impact its product launches and, thus revenues and profitability, would also be a negative trigger. Hence, in the future, the rating may be downgraded if there is any decline in the company’s revenues and profitability and/or an increase in debt levels, leading to an increase in net debt/ OPBDITA to above 1.0x on a sustained basis. Large debt-funded inorganic investments by the company or any adverse outcome of ongoing litigations would remain an event risk, and the impact of the same on the company’s business and credit profile would be monitored on a case-by-case basis.
- The company consistently maintains a decent dividend yield over the years. However, it's noteworthy that a significant portion of the shareholdings is held by the founders. This suggests that the founders are withdrawing wealth from the business rather than reinvesting it to enhance shareholder value.
Business Rating
Our Team
